{
  "ptid_time": "072_S_4057_2011-08-29",
  "img_path": "/data/qiuhui/data/adni/images/072_S_4057/2011-08-29/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 30,508 mm³, 35.1% below the reference mean. With a Z-score of -1.02 (15.4th percentile), this represents mild atrophy; whole brain volume measures 1,099,900 mm³, 6.9% above the reference mean. With a Z-score of 0.90 (81.6th percentile), this represents normal volume ; entorhinal cortex volume measures 2,659 mm³, 33.0% below the reference mean. With a Z-score of -2.16 (1.5th percentile), this represents significant atrophy; fusiform gyrus volume measures 17,406 mm³, 3.7% below the reference mean. With a Z-score of -0.32 (37.6th percentile), this represents normal volume ; middle temporal gyrus volume measures 17,566 mm³, 12.9% below the reference mean. With a Z-score of -1.16 (12.3th percentile), this represents mild atrophy. ",
  "text_data": "Age is 81.1 years. Gender is Male. Education: 16 years. Handedness: Right. Race: White. Medical history: Neurologic; Head, Eyes, Ears, Nose and Throat; Cardiovascular; Musculoskeletal; Allergies or Drug Sensitivities. MMSE: 26.0. MoCA: 22.0. Logical Memory: 4.0. Laboratory findings: Vitamin B12: 987.00 (significant elevated); Total Bilirubin: 0.80 (significant elevated). APOEε4 alleles: 1.0. Biomarker levels: Florbetapir (AV45): 1.66 SUVR (profound elevated); Amyloid beta: 950.80 pg/mL (normal ); Total tau: 533.00 pg/mL (profound elevated); Phosphorylated tau: 56.96 pg/mL (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging shows significant atrophy in the entorhinal cortex (Z-score -2.16, 1.5th percentile) and mild atrophy in the middle temporal gyrus and ventricles, which are regions commonly affected in Alzheimer’s disease (AD). The CSF biomarkers (profoundly elevated T-tau, P-tau, and AV45) strongly support AD pathology despite normal Aβ levels, which could indicate an atypical AD variant or advanced disease stage. The cognitive scores (MMSE 26, MoCA 22) suggest mild cognitive impairment, aligning with the structural and biomarker findings.  \n\n**Diagnosis:** **Dementia (likely Alzheimer’s disease)**  \n**Confidence:** **High** (due to concordance between biomarker evidence, atrophy patterns, and cognitive decline).  \n\n*Note:* The normal Aβ is atypical for typical AD but may reflect late-stage \"burnt-out\" amyloid deposition or a non-amyloidogenic AD subtype (e.g., primary age-related tauopathy [PART] or hippocampal-sparing AD). Further clinical correlation is advised.",
  "timestamp": "2025-07-26T09:15:47.075771"
}